Data Dictionary: Pancreatic cancer - DPCA

Go back to Dutch Institute for Clinical Auditing Databases (DICA) (The Netherlands) page.

This is a summary of the variables available in the database. You can download the complete data dictionary here: Click here to learn more.

Patient Demographics and Identification
Variables	Description
Zorginstelling	Healthcare Institution
Uniek Patiëntnummer	Unique Patient Number
Burger Service Nummer	Social Security Number
Geslachtsnaam	Surname
Geboortedatum	Date of Birth
Geslacht	Gender
Land (Woonadres)	Country (Country of Residence)
Postcode	Postal Code
Datum overlijden (indien van toepassing)	Date of Death (if applicable)

Comorbidities
Variables	Description
Comorbiditeiten	Comorbidities, with options to add a new record or update based on changes or previous registrations

Medical Procedures
Variables	Description
Verrichtingen	Procedures, where multiple procedures per patient can be registered if applicable

COVID-19 Module
Variables	Description
Deze generieke COVID-19 module	A generic COVID-19 module added due to the impact of the coronavirus crisis on the quality of care, allowing for the better interpretation of indicators during this period

Pathology Variables through PALGA
Variables	Description
In het kader van de PALGA-koppeling worden pathologie variabelen	Pathology variables automatically structured and included in the registration via the PALGA-pathology module, requiring no additional data

Patient Identification and Treatment Timeline
Treatment start date
Reason for registration
Hospital patient number

Patient Physical and Performance Metrics
Height in cm
Preoperative weight in kg
Weight loss in kg and period in weeks
ECOG performance status (Eastern Cooperative Oncology Group)

Laboratory Biomarkers

• Bilirubine in µmol/l
• Hemoglobine in mmol/l
• Albumine in g/l
• IgG4 in g/l
• Carcinoembryonic antigen (CEA) in µg/l
• CA19.9 in kU/l (Note: Last CA19.9 before the start of neoadjuvant treatment or surgery)

Imaging and Diagnostic Procedures

• CT, MRI, or MRCP performed
• Date of the last preoperative imaging
• Presence of a tumor in the pancreas or periampullary on CT or MRI
• Cystic features suggestive of malignancy
• Involvement of vessels and other structures on imaging

Histology and Cytology

• Preoperative PA number
• Method and date of obtaining the first positive cytology or histology
• Histological and cytological diagnoses

Multidisciplinary Team Consultations and Decisions

• Date of the last MDT (Multidisciplinary Team) discussion before treatment
• Working diagnosis and eligibility for surgical exploration

Treatment and Surgery Details

• Neo-adjuvant/induction treatment type and start date
• Operative details including ASA score, type of resection, and operative complications
• Postoperative pathology including tumor origin, size, and grade

Postoperative Management and Follow-Up

• Palliative treatments including chemotherapy and radiotherapy
• Date of discharge and any readmissions within 30 days
• Adjuvant therapy details and participation in oncological trials

SARS-CoV-2 Suspected or Confirmed Infection

• Presence of a clinical suspicion or test for SARS-CoV-2 infection prior to and up to 30 days post-admission.
• Date of the first suspicion of SARS-CoV-2 infection.
• Date of the first specific test for SARS-CoV-2 infection.
• Date of the first positive laboratory test for SARS-CoV-2.
• Final status regarding SARS-CoV-2 infection.

Preoperative and Postoperative COVID-19 Testing

• Number of preoperative RT-PCR tests and the date of the first test.
• Date of the first preoperative CT thorax with COVID-19 concern and CORADS 4-5 score.
• Number of postoperative RT-PCR tests and the date of the first test.
• Date of the first postoperative CT thorax with COVID-19 concern and CORADS 4-5 score.
• Definitive preoperative and postoperative COVID-19 status.

Patient Characteristics

• Symptoms indicative of COVID-19 (e.g., cough, fever, dyspnea, loss of smell/taste).
• Patient's smoking status and pack-years.
• Patient's height (in cm) and weight (in kg) at admission.

Surgical and Intensive Care Considerations

• Presence of preoperative COVID-19 related complications (e.g., ARDS, acute renal failure, arrhythmias, thromboembolic events).
• Impact on neoadjuvant treatment and changes in treatment plans or schedules.
• Impact on surgical approach (laparoscopic, robotic, open) due to COVID-19.
• Postoperative complaints consistent with COVID-19 and the number of days post-surgery they began.

ICU Admission Related to COVID-19

• Presence and type of ICU admission related to COVID-19.
• Type of respiratory support during ICU stay (e.g., prone ventilation, ECMO).
• ICU admission and discharge dates and durations.
• Destination after ICU discharge.

Sample Information

• Date of tissue arrival at laboratory
• Pathology laboratory
• Pathology number (TJJ-CCCCCC)
• Protocol
• Sample number

Diagnostic Details

• Is cytology or histology obtained during the diagnostic process?
• Most likely origin of the tumor
• Histological diagnosis?

Tumor Characteristics

• Largest tumor diameter in cm
• Smallest margin in cm (radicality)
• Tumor differentiation grade
• Neuroendocrine tumor differentiation grade
• pT-stage pancreatic carcinoma according to TNM8
• Papil of Vater carcinoma according to TNM8
• Distal cholangiocarcinoma according to TNM8
• Duodenum carcinoma according to TNM8 small intestine

Lymph Node and Metastasis Information

• Number of lymph nodes found
• Number of tumor-positive lymph nodes found
• Distant metastases?

Response to Treatment

• Pathological response after neoadjuvant therapy with Histological Tumor Regression Grading (HTRG)